FibroBiologics Announces Advances in Burn Treatment Using Proprietary Fibroblast Spheroid Technology
FibroBiologics, Inc. (Nasdaq: FBLG) ('FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures ...
Researchers from Australian National University and Longi used photoluminescence imaging to analyze dopant distributions in RCz-grown silicon wafers doped with antimony, phosphorus, and gallium, ...
Company plans to initiate a pivotal phase 3 clinical trial of aglatimagene besadenovec (aglatimagene or CAN-2409) in patients with progressive, metastatic, non-squamous, non-small cell lung cancer ...
FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development ...
MajesTEC-9 supports moving teclistamab earlier in myeloma treatment, with robust PFS and OS gains over standard care in the second-line setting, notes Roberto Mina, MD. AJMC: Given the 71% reduction ...
The market for radioligand therapies is expected to grow significantly in the coming years. This is due to the increasing number of patients who are being diagnosed with cancer, the growing ...
6hon MSN
A common hydrogel may be built differently than assumed, with big implications for mechanics
A study led by Northwestern University researchers has reported a way to observe hydrogel nano and microstructure while the hydrogel remains fully solvated. The approach reveals that methylcellulose, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results